Evidence map›Paper›PMID 27653163›Full record

ReviewCurrent opinion in gastroenterology2016

Gastrointestinal defense mechanisms.

Hyder Said, Jonathan D Kaunitz

Abstract readReview
In one paragraph

Review in Current opinion in gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hyder SaidaCollege of Letters & Sciences, University of California, Los Angeles bResearch Service, West Los Angeles VAMC cDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Jonathan D Kaunitz

Funding

Duodenal Muscosal Defense MechanismsR01DK054221 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAUNITZ, JONATHAN D. · 1999 to 2016
$4.4M
Luminal Factors Affecting Duodenal Protection and ChemosensingI01BX001245 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI KAUNITZ, JONATHAN D. · 2012 to 2025
–
BLRD VA I01 BX001245NIDDK NIH HHS R01 DK054221
6 · The paper itself

Abstract

purpose of reviewTo summarize and illuminate the recent findings regarding gastroduodenal mucosal defense mechanisms and the specific biomolecules involved in regulating this process, such as glucagon-like peptides (GLPs). RECENT

findingsThere has been a growing interest in luminal nutrient chemosensing and its physiological effects throughout the digestive system. From the ingestion of food in the oral cavity to the processing and absorption of nutrients in the intestines, nutrient chemosensing receptors signal the production and release of numerous bioactive peptides from enteroendocrine cells, such as the proglucagon-derived peptides. There has been a major emphasis on two proglucagon-derived peptides, namely GLP-1 and GLP-2, due to their apparent beneficial effect on gut structure, function, and on metabolic processes. As an incretin, GLP-1 not only enhances the effect and release of insulin on pancreatic βcells but also has been implicated in having trophic effects on the intestinal epithelium. In addition, GLP-2, the other major proglucagon-derived peptide, has potent intestinotrophic effects, such as increasing the rate of mucosal stem cell proliferation, mucosal blood flow, and fluid absorption, as well as augmenting the rate of duodenal bicarbonate secretion to improve gastric mucosal health and longevity. SUMMARY: Understanding the mechanisms underlying nutrient chemosensing and how it relates to GLP release can further elucidate how the gut functions in response to cellular changes and disturbances. Furthermore, a more in-depth comprehension of GLP release and its tissue-specific effects will help improve the utility of GLP-1 and GLP-2 receptor agonists in clinical settings. This, in turn, should help patients suffering from intestinal failure, malabsorption, and mucosal injury.

Indexed as

Clinical Trials as TopicGastric MucosaGastrointestinal DiseasesGlucagon-Like Peptide 1Glucagon-Like Peptide 2Glucagon-Like PeptidesHumansIntestinal MucosaNutritional Physiological PhenomenaGlucagon-Like Peptide 1Glucagon-Like Peptide 2Glucagon-Like Peptides

Identifiers

PMID27653163
PMCPMC5667561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.